Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $2.50 price target on the stock.
Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results [Yahoo! Finance]
Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall [Yahoo! Finance]
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall